FDA Approves Allergan’s Drug for Longer Eyelashes
Allergan Inc, maker of Botox, said on Friday that the U.S. Food and Drug Administration has approved its eyelash-thickening drug Latisse. Reuters Health Information (Source: Medscape Medical News Headlines)
Read the original post:
FDA Approves Allergan’s Drug for Longer Eyelashes
Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse — First and Only Treatment Approved by the FDA for Hypotrichosis of…
IRVINE, Calif.–(BUSINESS WIRE)–Dec 26, 2008 – Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Latisse (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes
FDA OKs 1st Eyelash Drug Latisse
Title: FDA OKs 1st Eyelash Drug LatisseCategory: Health NewsCreated: 12/29/2008Last Editorial Review: 12/29/2008 (Source: MedicineNet Eyesight General) MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network , and receive $5 free advertising.
Originally posted here:
FDA OKs 1st Eyelash Drug Latisse
FDA OKs Latisse For Hypotrichosis of Eyelashes Treatment
New prescription drug Latisse increases the length, thickness and darkness of eyelashes.
See the original post here:
FDA OKs Latisse For Hypotrichosis of Eyelashes Treatment
Allergan Eyelash Enhancer Approved
Allergan received FDA approval to market Latisse, a beauty treatment that increases the length, thickness and darkness of eyelashes by using a drug the company developed to treat glaucoma. (Source: WSJ.com: Health)
Originally posted here:
Allergan Eyelash Enhancer Approved
Allergan Gets Nod For Eyelash Treatment
Eye care and cosmetic drug maker Allergan on Friday said its eyelash growth treatment Latisse received Food and Drug Administration approval,… (Source: Investor’s Business Daily: HEALTH)
Read more:
Allergan Gets Nod For Eyelash Treatment
(sponsored multimedia) Latisse™ (bimatoprost ophthalmic solution) 0.03%: A National Summit on New Aesthetic Opportunities
(Source: Modern Medicine)
Read this article:
(sponsored multimedia) Latisse™ (bimatoprost ophthalmic solution) 0.03%: A National Summit on
New Aesthetic Opportunities
FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes
IRVINE, Calif.–(BUSINESS WIRE)–Dec 5, 2008 – Allergan, Inc. today announced the U.S.
